AIM ImmunoTech Inc.
AIM
$1.47
$0.075.00%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -41.05% | -39.80% | -24.35% | -15.84% | -1.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -41.05% | -39.80% | -24.35% | -15.84% | -1.55% |
| Cost of Revenue | 163.89% | -39.66% | -34.00% | -26.19% | 20.00% |
| Gross Profit | -88.96% | -39.86% | -20.98% | -13.13% | -5.52% |
| SG&A Expenses | -50.08% | -49.63% | -44.71% | -34.59% | 46.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -47.78% | -47.37% | -46.93% | -37.91% | 18.80% |
| Operating Income | 47.83% | 47.42% | 47.06% | 38.05% | -18.97% |
| Income Before Tax | 34.18% | 42.36% | 51.13% | 40.20% | -15.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 34.18% | 42.36% | 51.13% | 40.20% | -15.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 34.18% | 42.36% | 51.13% | 40.20% | -15.18% |
| EBIT | 47.83% | 47.42% | 47.06% | 38.05% | -18.97% |
| EBITDA | 48.21% | 47.80% | 47.41% | 38.36% | -19.73% |
| EPS Basic | 58.15% | 56.87% | 61.72% | 48.11% | -10.19% |
| Normalized Basic EPS | 59.53% | 56.46% | 61.57% | 48.78% | -12.89% |
| EPS Diluted | 58.15% | 56.87% | 61.72% | 48.49% | -9.08% |
| Normalized Diluted EPS | 59.53% | 56.46% | 61.57% | 48.78% | -12.89% |
| Average Basic Shares Outstanding | 37.94% | -8.03% | -30.69% | -41.05% | -48.62% |
| Average Diluted Shares Outstanding | 37.94% | -8.03% | -30.69% | -41.05% | -48.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |